Ratings Cellectis S.A.

Equities

ALCLS

FR0010425595

Market Closed - Euronext Paris Other stock markets 11:35:09 2024-04-24 am EDT			5-day change	1st Jan Change
2.405 ^EUR	-0.62%		+2.56%	-12.99%

Apr. 24	European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	MT
Apr. 22	Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs	CI

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

The prospective high growth for the next fiscal years is among the main assets of the company
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Historically, the company has been releasing figures that are above expectations.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
One of the major weak points of the company is its financial situation.
The company's "enterprise value to sales" ratio is among the highest in the world.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
CELLECTIS S.A.	-12.99%	186M	C
IQVIA HOLDINGS INC.	+4.09%	43.43B	B
LONZA GROUP AG	+47.81%	41.69B	A
MODERNA, INC.	+9.45%	41.31B	B-
CELLTRION, INC.	-10.92%	27.14B	C
ICON PUBLIC LIMITED COMPANY	+9.32%	25.28B	B-
ALNYLAM PHARMACEUTICALS, INC.	-24.87%	18.47B	B
MEDPACE HOLDINGS, INC.	+29.70%	12.59B	C+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.28%	12.33B	C+
UNITED THERAPEUTICS CORPORATION	+7.78%	11.03B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes